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This study involves the development of thin oral solvent cast films for the potential delivery of 
the proton pump inhibitor, omeprazole (OME) via the buccal mucosa for paediatric patients. 
OME containing films were prepared from ethanolic gels (1% w/w) of metolose (MET) with 
polyethylene glycol (PEG 400) (0.5% w/w) as plasticiser, and L-arg (0.2% w/w) as a stabilizer 
and dried in an oven at 40°C. The blank and drug loaded films were divided into two groups, 
one group was subjected to supercritical carbon dioxide (scCO2) treatment and the other group 
untreated. The untreated and scCO2 treated films were then characterised using differential 
scanning calorimetry, thermogravimetric analysis, scanning electron microscopy, X-ray 
diffraction, Fourier transform infrared spectroscopy, hydration (swelling), mucoadhesion and 
in vitro drug dissolution studies. Treatment of the solvent cast films with scCO2 caused 
significant changes to the functional and physical properties of the MET films. The original 
drug loaded MET films showed a sustained release of OME (1 hour), whereas scCO2 treatment 
of the formulations resulted in fast dissolving films with more than 90% drug release within 15 
minutes.  
 
Key Words: Supercritical carbon dioxide, Omeprazole, Metolose, Buccal, Pediatric, fast 
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There has been a growing interest in the design and development of novel formulations that 
are age appropriate particularly for paediatric and geriatric patients with swallowing difficulties 
[Lopez et al., 2015]. Various formulations have been proposed to address this challenge 
including sublingual tablets, fast disintegrating tablets, buccal films and wafers. These have 
the advantage of being able to hydrate or dissolve in saliva to release the drug for absorption 
through the sublingual / buccal mucosa or more easily swallowed when compared to large 
volumes of liquids or whole tablets. Liu and co-workers in a review discussed the formulation 
factors affecting the acceptability of traditional oral medicines (e.g. tablets, capsules, liquids) 
in children including dysphagia (difficulty in swallowing) and flexibility of oral dosage forms. 
The review concluded that paediatric populations will benefit from novel formulations 
(including films) that overcome these challenge, such as getting the right formulation for the 
right age group, taste, smell and palatability. (Liu et al., 2014). In addition, these solid 
formulations are also suitable for drugs that are unstable in liquid or semi-solid dosage forms. 
Furthermore, buccal or sublingual absorption avoids gastric acid degradation and hepatic first 
pass metabolism, which allows administration of lower doses.  
A good drug candidate for such application is the proton pump inhibitor omeprazole (5-
methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole) 
which is an inhibitor of gastric acid secretion. Omeprazole (OME) is an effective short-term 
treatment for gastric and duodenal ulcers and used in combination with antibiotics for 
eradication of Helicobacter pylori (Stroyer et al., 2006). Its stability in aqueous solution is 
entirely dependent on the initial pH and, it is rapidly degraded in acidic and neutral conditions 
but shows greater stability in alkaline medium. We have previously shown the potential of 
OME based buccal films for sustained delivery of via the buccal mucosa for paediatric 
administration (Khan et al., 2015) and demonstrated the release and permeation of the drug 
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across pig buccal membrane (Khan et al., 2016). However, though OME is well absorbed from 
the gastrointestinal tract its oral bioavailability in humans of about 50% which suggests first 
pass metabolism for this drug. Therefore oral mucosa (buccal / sublingual) absorption 
combined with residual GIT absorption could constitute a potential approach for improving its 
oral bioavailability whilst also improving compliance in patients with difficulty in swallowing. 
Choi and co-workers developed buccal adhesive tablets composed of sodium alginate, HPMC 
and croscarmellose sodium and loaded with OMEand investigated the buccal permeation of 
the drug across hamster cheeks. They showed that plasma concentration of OME increased 
reached a maximum of 370 ng/ml in 45 min after buccal administration with an absolute buccal 
bioavailability of omeprazole in hamsters of 13.76% (Choi et al., 2000). In another study, 
permeation of OME incorporated into different Cyclodextrins with and without L-arginine, 
through pig buccal mucosa was investigated (Figueiras et al., 2009). The showed that the 
amounts (µg) of drug permeating per cm2/ hour (flux) increased when L-arginine was present, 
due to its stabilizing effect on the inclusion complex formed. The flux values they reported 
were OME (2.382 µg/cm2/h), OME_βCD (2.685 µg/cm2/h), OME_MBCD (3.455 µg/cm2/h), 
OME_βCD + Arg (4.161 µg/cm2/h), OME_MβCD + Arg (5.588 µg/cm2/h). 
 Proton pump inhibitors (PPIs) such as OME block the hydrogen/potassium adenosine 
triphosphatase enzyme situated in the stomach wall thus inhibiting acid secretion, giving relief 
from ulcers of the oesophagus, stomach and duodenum and from gastro-oesophageal reflux 
disease (GERD). PPIs change their own chemical formula with the addition of H+/K+ adenosine 
triphosphatase enzyme in the parietal cells, resulting in the formation of active chemical 
derivative by gaining a proton (H+), which increases the pH of the stomach and reduces acid 
secretion from the wall of the stomach. The new protonated chemical compound also possesses 
the ability to bind with the parietal cells in the stomach wall, thus reducing further acid 
secretion (Chapman et al., 2011). Therefore systemic action following administration and 
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absorption across alternative routes such as oral mucosa membranes is possible using 
appropriate formulations. For example, Widder and co-workers patented unidirectional films 
and tablets for the delivery of proton pump inhibitor across the oral mucosa (Widder et al., 
2004). Mansuri and co in their review, reported that buccal mucoadhesive formulations are 
potential means delivering PPIs as a means of avoiding degradation in the gastrointestinal tract 
when administered orally (Mansuri et al., 2016). 
In recent years, the application of supercritical fluid technology in formulation 
development has shown tremendous success in the field of drug delivery (Bruner, 2010; 
Tabernero et al., 2012). A supercritical fluid (SCF) can be defined as a substance above its 
critical pressure (Pc) and temperature (Tc) where it exists as a single phase and possesses 
properties of both liquids and gases (Knez et al, 2015). The liquid-like density of SCF provides 
solvent power similar to a light hydrocarbon and its gas-like viscosity allows excellent mass 
transfer and higher diffusivity in a material (Shivonen et al., 1999). A number of different SCFs 
have been used in various applications such as organic synthesis, cleaning and materials 
processing [Tabernero et al., 2012; Duarte et al., 2015]. However, carbon dioxide (CO2) 
remains the most widely used SCF because of the advantages such as being environmentally 
benign, non-toxic, non-flammable, non-corrosive, readily available, affordable and easy to  
remove from the reaction systems in comparison to organic solvents. The low Tc (31.15°C) and 
Pc (or 73.8 bar) of CO2 makes it an ideal solvent for the processing of numerous pharmaceutical 
compounds (Ginty et al., 2005). Supercritical carbon dioxide (scCO2) is known to be an 
excellent solvent for numerous low molecular weight non-polar compounds as well as some 
polar compounds [Mohamed et al., 2011]. It also has good solubility of selected groups of 
polymers such as amorphous fluoropolymers and silicones [Kendall et al., 1999]. Moreover, 
scCO2 is also capable of acting as a swelling or plasticising agent by dissolving in a polymeric 
matrix (Cooper, 2000).   
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The applications of SCFs are widely reported for several pharmaceutical operations 
including crystallisation, micronisation, coating, product sterilisation and drug–cyclodextrin 
complexation (Rudrangi et al., 2015). Similarly, it has also been successfully applied in the 
development of thin films and scaffolds (Falk et al., 1997; Yanez et al., 2011; Cooper 2003; 
Kiran, 2016). Processing with scCO2 can impart interesting characteristics in thin films and 
scaffolds in terms of porosity, pore structures and crystallinity. Aydin et al, (2006) synthesised 
a copolymer of L-lactide and epsilon-caprolactone and used the resultant polymer to prepare 
composite films. Subsequently, the films were treated with scCO2 to prepare highly porous 
sponges for potential use as scaffolds in tissue engineering. They reported that the scaffold pore 
sizes ranged between 40-80µm and showed that the scCO2 fabricated scaffolds possessed 
enhanced cell adhesion, proliferation and differentiation of L929 fibroblast cell line culture. 
Rinki and co-workers prepared porous chitosan scaffolds for cell culture, by reacting chitin 
with alkali in the presence of (scCO2) (Rinki et al., 2009). Composite chitosan-
nanohydroxyapatite based scaffolds have also been prepared by means of scCO2 treatment 
(Karakeçili & Arıkan, 2012). In their study, nanohydroxyapatite particles were added to acetic 
acid based chitosan gels which were subsequently frozen, dried with acetone and treated with 
supercritical fluid which yielded porous scaffolds, with potential for use in bone tissue bio-
engineering applications. The application of scCO2 in the formulation of scaffolds and effect 
of associated parameters (e.g. pressure and temperature) on such systems are very well reported 
in the scientific literature but studies on the effect of scCO2 processing on thin films for drug 
delivery purposes are scanty.   
The aim of this study was to investigate the effect of scCO2 processing on blank (BLK) 
and drug loaded (DL MET) films and compare their properties with the non-treated films. The 
films (both scCO2 treated and non-treated) have been functionally characterised for their 
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surface morphology, water content, physico-chemical (crystalline/amorphous nature; physical 
interactions), hydration (swelling), adhesive and OME dissolution properties. 
 
2 Materials and Methods 
2.1 Materials 
Metolose (MET) was obtained as a gift from Shin Etsu (Stevenage, UK), polyethylene glycol 
(PEG 400), L-arginine (L-arg) and gelatine were all obtained from Sigma-Aldrich (Gillingham, 
UK). Ethanol, potassium dihydrogen phosphate and sodium hydroxide were purchased from 




2.2.1 Formulation (gel and film) development 
Preliminary 1% w/w gels were prepared by adding the required weight of polymer (MET) to 
the relevant solvent (20% v/v ethanol) at room temperature. The polymeric gel was heated to 
40°C following complete hydration. Based on the total weight of polymer, the plasticiser (PEG) 
was added to obtain 0.5% w/w concentrations in the final gel. The resultant gel was cooled to 
room temperature and left stirring on a water bath for 30 minutes to achieve a homogeneous 
dispersion and then left overnight to remove all entrapped air bubbles. 
Once a clear homogeneous gel was obtained, 20g was gently poured into Petri dishes 
(86mm diameter) and kept in a pre-heated oven at 60°C for 24 hours. The dried films were then 
carefully peeled off from the Petri dish and photographs taken using a digital camera. Films 





2.2.2 Formulation of OME loaded films 
The OME-loaded films were obtained by initially preparing MET gels as described above. 
However, the drug was added to the appropriate volume of 20% v/v ethanol to form an OME 
solution (0.1% w/w). Due to the breakdown of OME following gel formation, L-arg was used 
as a stabilising agent to prevent drug degradation. This step was performed by adding L-arg 
(0.20% w/w) to the drug solution keeping the original OME concentration (0.10% w/w) 
constant. The polymer was then added slowly to the vigorously stirred OME-L-arg drug 
solution at room temperature to obtain the drug loaded gels and PEG added. The resulting gels 
were covered with parafilm and left overnight to allow air bubbles to escape, then 20g was 
poured into Petri dishes and dried at 40°C.  
 
2.2.3 scCO2 processing of thin films 
Supercritical carbon dioxide (scCO2) treatment of the films was carried out on a Thar 
Technology Inc instrument containing a 150ml high pressure vessel. BLK and DL films were 
cut into 2cm2 strips and placed in a glass vial. The vial containing the thin film was placed in 
the high pressure vessel preheated to 40°C. The CO2 was then introduced into the chamber and 
pressure was slowly increased to 100 bar. These chosen conditions were mild and also allowed 
desired miscibility between scCO2, ethanol and water required for successful drying of thin 
films studied in this work (Brunner, 2010; Quiño et al., 2016). The system was allowed to 
equilibrate for 15 minutes once the required pressure was achieved. The CO2 pump was stopped 
and the chamber was depressurized at a rate of 7g/min with the help of automated back pressure 
regulator (ABPR). After complete depressurisation, the sample was removed from the high 
pressure vessel, digitally photographed and stored in poly bags and placed in a desiccator over 




2.2.4 Differential scanning calorimetry (DSC)  
DSC was used to characterise the thermal behaviour of the films and changes in their properties 
with introduction of PEG and drug. Analysis of the films and starting materials were carried 
out on a Q2000 (TA Instruments) calorimeter. About 2.5mg of each sample was placed into 
hermetically sealed Tzero aluminium pans with a pin hole in the lid and heated from -40°C to 
180°C at a heating rate of 10°C/min under constant purge of nitrogen (100mL/min).  
 
2.2.5 Thermogravimetric analysis (TGA)  
TGA studies were performed using a Q5000 (TA Instruments) thermogravimetric analyser. 
About 1-2.5mg of films (BLK and DL) was placed into hermetically sealed Tzero aluminium 
pans with a pin hole in the lid. Samples were heated under nitrogen atmosphere at a flow rate 
of 25ml/min from ambient temperature to 600°C at a heating rate of 2°C/min. 
 
2.2.6 Scanning electron microscopy (SEM) 
SEM was used to investigate the surface morphology of the films and to check for film 
uniformity and the presence of any cracks. The films were analysed using a Hitachi Triple 
detector CFE-SEM SU8030, (Roland Schmidt, Hitachi High-Technologies Europe, Germany) 
scanning electron microscope. Films were mounted onto Agar Scientific G301 aluminium pin-
type stubs (12mm diameter) with Agar Scientific G3347N double-sided adhesive carbon tapes 
and chrome coated (Sputter Coater S150B, 15nm thickness). The coated films were analysed 
at accelerating voltage of 2kV. 
 
2.2.7 X-ray diffraction (XRD) 
XRD was used to investigate the physical form (crystalline or amorphous) of the films (BLK 
and DL). XRD patterns of films and starting materials were obtained with a DIFFRAC plus 
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instrument (Bruker Coventry, UK) equipped with an XRD commander programme. A Goebel 
mirror was used as monochromator which produced a focused monochromatic CuKα1&2 
primary beam (λ=1.54184Å) with exit slits of 0.6mm and a Lynx eye detector for performing 
the experiment. The operating conditions during the experiment were 40kV and 40mA. Film 
samples were prepared by cutting into 2cm2 square strips, mounted on the sample cell and 
scanned between 2 theta of 0° to 70° and counting time of 0.1 second step size. 
 
2.2.8 Attenuated total reflectance (ATR) Fourier transform infrared (ATRFT-IR) 
spectroscopy  
FT-IR spectra were obtained using a Spectrum Two Perkin Elmer spectrophotometer (Perkin 
Elmer, US) equipped with a crystal diamond universal ATR sampling accessory (UATR). 
Before each measurement, the ATR crystal was carefully cleaned with ethanol. During the 
measurement, the sample was in contact with the universal diamond ATR top-plate. For each 
sample, the spectrum represented an average of 4 scans recorded in the range 4000-400cm-1. 
 
2.2.9 Hydration behaviour 
The hydration (swelling) capacities of the formulated (BLK and DL films were determined by 
incubating the samples in 10mL of 0.01M PBS solution (pH 6.8 ± 0.1 simulating salivary pH) 
set at 37 ± 0.1°C. The buffer solution was prepared by dissolving 6.8g of potassium dihydrogen 
phosphate in 1L of deionised water and adjusting the pH to 6.8 using sodium hydroxide 
(NaOH). The films were cut into 2cm2 strips and placed into small Petri-dish containing10mL 
of the media (PBS) and initially weighed. At predetermined time intervals of 5 minutes the 
liquid media was removed using a syringe and weighed again. Before the films were weighed 
excess buffer solution was blotted off with tissue. After weight had been recorded, 10mL of 
fresh buffer solution was placed back in the Petri dish using a syringe. These studies were 
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performed in triplicate (n = 3) for each set of formulated samples and average values were 
calculated.  
 
The swelling capacity determined by calculating the swelling index (%) using the equation 
below: 









The in vitro mucoadhesion experiments were performed for BLK and DL films with a TA HD 
plus Texture Analyser (Stable Micro Systems, Surrey, UK) fitted with a 5kg load cell. The film 
was attached to an adhesive rig probe (75mm diameter) with double sided adhesive tape. An 
88mm diameter Petri dish was used containing 20g gelatine solution (6.67% w/w) allowed to 
set as a solid gel and the surface of the gel was equilibrated with 0.5mL of PBS (pH 6.8) to 
represent the buccal mucosa surface and saliva conditions (Kianfar et al., 2014). The texture 
analyser was set to tensile mode and the probe set to approach the model buccal mucosal 
surface with set parameters for adhesivity using the following settings: pre-test speed 0.5mm/s; 
test speed 0.5mm/s; post-test speed 1.0mm/s; applied force 1N; contact time 60.0 seconds; 
trigger type auto; trigger force 0.05N and return distance of 10.0mm. Texture Exponent 32 
software was used to record and process the data. The peak adhesive force (PAF) required to 
separate the film from the mucosal surface was determined by the maximum force. The area 
under the curve (AUC) representing the total work of adhesion (TWA) was estimated from the 
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force-distance plot whiles the cohesiveness of the sample was determined by the distance of 
travel. 
 
2.2.11 In vitro release of OME using Franz-type diffusion cell 
Before the dissolution studies, drug assay and uniformity of OME within the film was 
determined. This was measured by weighing the film accurately to 5mg (n=3) and hydrated in 
8ml of drug dissolution media (0.01M PBS pH 6.8 at 37°C). The hydrated film was stirred at 
37 ± 0.5°C until completely dissolved. The concentration of OME was analysed using HPLC. 
In vitro drug dissolution studies were carried out using Franz-type diffusion cells. 5mg of MET 
DL film was placed in the donor compartment on stainless steel wire mesh which separated the 
donor and receiver compartments, with the mucoadhesive surface in contact with the wire mesh 
and facing the receiver compartment of the Franz diffusion cell (Cui et al., 2008). The receiver 
chamber was filled with 8mL of 0.01M PBS pH 6.8 at 37°C with magnetic stirring at a speed 
of 250 rev/min. The chambers were held together by a cell clamp and sealed with parafilm, in 
order to limit evaporation and the temperature of the diffusion cell was maintained at 37 ± 
0.5°C and stirred throughout the experiment. Though bicarbonate is the major buffering agent 
in saliva, we employed phosphate buffer as we previously used simulated saliva based on a 
previously published work which employed sodium dihydrogen phosphate and therefore we 
had to use PBS to compare with behaviour in the simulated saliva to allow consistency of buffer 
ions present. 
Aliquots (1mL) of the dissolution medium was sampled at predetermined time intervals 
and replaced with the same amount of fresh medium to maintain a constant volume for 2 hours. 
The sampled dissolution medium was measured using HPLC as described below. The 
concentration of OME released from the film was determined by interpolation from the 
linearized calibration curve (R2 > 0.99) and cumulative percentage drug release profiles plotted. 
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The dissolution profiles were further compared using the time to release 20% of the drug (t20%) 
and the mean percentage release at 15 minutes (t15min).   
 
2.2.12 HPLC analysis 
Concentration of DL films as well as drug release in dissolution studies were analysed using 
an Agilent 1200 HPLC equipped with an auto sampler (Agilent Technologies, Cheshire, UK,) 
with a Chemstation® software program. The stationary phase used was a Hypersil™ ODS C18 
HPLC column, 5µm particle size (250 x 4.6mm) (Thermo Scientific, Hampshire UK). The 
mobile phase consisted of a mixture of ammonium acetate and acetonitrile in the ratio of 
60:40v/v. The flow rate of the mobile phase was maintained at 2ml/min and detector 
wavelength for OME was set at 302nm respectively. 20μl volumes were injected during each 
run. Standards from 10-50μg/ml were used to plot calibration curves for OME (R2> 0.99). 
 
3 Results  
3.1 Supercritical fluid (CO2) treated films 
Figure 1 shows the visual appearance of both BLK and DL films before and after treatment 
with scCO2. The preliminary observation of the formulated films (BLK and DL) treated in 
scCO2, showed a slight difference in the colour, texture and apparent physical strength of the 
scCO2 treated films compared to the untreated films. The scCO2 treated BLK films showed a 
rough surface whereas DL films were slightly yellow in colour and more opaque compared to 
the non-treated films. 
 
3.2 Differential scanning calorimetry (DSC)  
Figures 2a and 2b respectively show the DSC thermograms of BLK and DL MET films treated 
with scCO2 compared with non-scCO2 treated original films. In Figure 2a the thermogram of 
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scCO2 treated BLK film was characterised by a broader endothermic peak at 56.57°C, and no 
definite melt or glass transition peaks was obtained and was similar to that of non-treated BLK 
film which showed a peak at 56.67°C. The thermograms presented in Figure 2b for DL film 
treated in scCO2 also showed a broad endothermic peak at 63.31°C, followed by another 
endothermic peak at 133.49°C, indicating the melting of possibly recrystallized OME. This 
observation was different from the non-treated DL film which showed a broad peak at 83.41°C, 
followed by another endothermic peak at 151.82°C which could represent depressed melting 
point of trace amounts of crystalline OME whilst the rest largely remained amorphous.  
 
3.3 Thermogravimetric analysis (TGA)  
TGA was used to determine the equilibrium residual moisture content (%) of both the scCO2 
treated and untreated BLK and DL MET films. As seen in table 1 the highest percent moisture 
content was observed in scCO2 treated DL MET film at 5.91% which was higher than non-
scCO2 treated DL MET film (5.14%). However, in the case scCO2 treated BLK MET film, the 
reverse was true with a residual moisture content of 3.16% which was again higher than the 
non-scCO2 treated films (1.99%) and the difference was statistically significant (p < 0.05).  
 
Table 1 TGA results showing weight loss observed for DL MET films from ethanolic (20 % 
v/v EtOH), PEG 400 (0.5 % w/w) gels containing OME: L-arg (1:2) treated with and without 
scCO2. 
Films Weight loss (%) 
BLK MET film (non- scCO2 treated) 1.99 
BLK MET film (scCO2 treated) 3.16 
DL MET film (non-scCO2 treated) 5.14 
DL MET film (scCO2 treated) 5.91 
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3.4 Scanning electron microscopy (SEM) 
The surface morphology and topographic characteristics of BLK and DL MET films were 
evaluated using SEM. Figures 3a and 3b show micrographs of the pure OME and L-arg. Figure 
3c shows rough and lumpy surfaces for scCO2 treated BLK film compared to the untreated 
BLK film (data not shown). Micrographs obtained for DL films treated with scCO2 (Figure 3d) 
also had rough surface with presence of crystals compared to the untreated DL film (data not 
shown) which was smooth and homogenous.  
 
3.5 X-ray diffraction (XRD) 
XRD analysis was performed to determine the crystalline - amorphous ratio and confirm the 
physical form of the various components within the films. Figures 4a and 4b, show the XRD 
diffractograms of BLK and DL films with and without scCO2 treatment. The results clearly 
suggest that there is no difference between the BLK films treated with scCO2 and non-treated 
equivalent, whilst DL MET films treated with scCO2 showed 5% crystallinity compared to 
non-treated film which was completely amorphous. Figures 5a and 5b show the XRD-
diffractograms for the pure starting materials and their physical mixtures respectively. XRD 
diffractograms for the pure starting materials showed that MET and PEG 400 were amorphous 
in nature whilst OME and L-arg were highly crystalline. 
 
3.6 ATR- (FT-IR) spectroscopy  
Figures 6a and 6b show the FT-IR spectra for BLK and DL MET films treated with and without 
scCO2. There were differences observed in the FTIR profiles of scCO2 treated films compared 
to non-scCO2 films as evident from the major peaks listed in tables 2 and 3. Some of the main 
peaks disappeared whilst others shifted to higher wavenumber and in some cases new peaks 
appeared that were not originally present in the corresponding non-treated film. In the case of 
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the BLK films (table 2), all the peaks present in the non-treated films were also present in the 
scCO2 treated films, however, two unique peaks appeared at 1314.06 and 1642.42cm
-1 for the 
scCO2 treated films, which were completely absent in the non-treated films. For the DL films, 
a different observation was made in that unique peaks were observed in both the scCO2 treated 
and non-treated films (table 3). The non-treated DL films showed two peaks at 1059.40 and 
1204.25cm-1 which were completely absent in the corresponding scCO2 treated films, whilst 
the scCO2 treated DL films showed three peaks at 1310.40, 1375.02 and 1453.21cm
-1 that were 
completely absent in the non-treated equivalent. Further, the three unique peaks in the scCO2 
treated DL films were also absent in the scCO2 treated BLK films.  
 
Table 2 Comparing and contrasting the major FTIR peaks of interests for plasticised BLK 
MET films showing effect of scCO2. The main peaks present in scCO2 treated films but 
missing from the non-treated films are highlighted in bold font. 
Non- scCO2 treated scCO2 treated 
Peak No. cm-1 %T Peak No. cm-1 %T 
1 3436.89 82.77 1 3445.31 86.97 
2 2876.04 78.65 2 2899.32 84.70 
3 - - 3 1642.42 93.99 
4 1454.96 84.38 4 1454.86 86.28 
5 1349.02 82.95 5 1374.15 83.93 
6 -  6 1314.06 86.33 
7 1057.70 24.61 7 1053.56 27.98 





Table 3 Comparing and contrasting the major FTIR peaks of interests for DL MET films. The 
main peaks present in scCO2 treated films but missing from the non-treated films and vice 
versa are highlighted in bold font. 
Non- scCO2 treated scCO2 treated 
Peak No. cm-1 %T Peak No. cm-1 %T 
1 3436.11 87.32 1 3374.27 85.32 
2 2877.31 83.30 2 2926.33 82.47 
3 1628.42 80.65 3 1630.45 78.84 
4 1554.01 81.28 4 1561.06 79.46 
5 - - 5 1453.21 78.15 
6 1406.59 81.93 6 1404.00 78.84 
7 1204.25 82.33 7 1375.02 77.62 
8 - - 8 1310.40 80.89 
9 1059.40 49.64 9 1055.37 34.88 
10 945.33 72.55 10 945.78 65.01 
 
3.7 Hydration (swelling) capacity 
The untreated BLK and DL MET films showed a swelling index of 1841% and 2630% 
respectively in 20 minutes. In the case of scCO2 treated films, there was not enough time to 
weigh the swollen gel to calculate percent swelling index for the films as they disintegrated 
within seconds (25 seconds for BLK films and 40 seconds for DL films) of coming in contact 






The mucoadhesion results (Figures 7a and 7b) show that in all cases, the non-treated BLK and 
DL films recorded higher adhesive values (cohesiveness, PAF and TWA) than the scCO2 
treated films.  
 
3.9 In vitro release of OME using Franz-type diffusion cell 
Figure 8 shows the dissolution profiles of scCO2 treated and non-treated DL MET films in PBS 
(pH 6.8).  The scCO2 treated DL film showed higher cumulative release (94% in 10 minutes) 
than non- treated DL films (70% in 60 minutes).  
 
3.10 Comparison of release profiles 
In this study, the time to release 20% of the drug (t20%) and the percentage cumulative release 
at 15 minutes (t15min) were used to compare the DL scCO2 treated and non-treated films (Costa 
et al, 2001) and results are shown in table 4. The results showed that scCO2 treated DL film 
released 20% of OME within 0.6 minutes whereas non-treated scCO2 DL film took 5.5 minutes 
to release the same percentage of the drug. Further, within 15 minutes, non-treated DL film 
released up to 55% and whilst scCO2treated DL film released 92% of drug which is a significant 
difference (p < 0.05)  
Table 4 A comparison of the time to release 20% of drug (t20%) and the amount of drug released 
after 15 minutes (t15 min) from both scCO2 treated and non-treated DL MET films. 
DL MET films  
Time to release 20% of drug 
(t20%) 
Mean % release at 15 min 
(t15min) 
Non-treated 5.5 55 





In the current study, the effect of scCO2 treatment on the functional physico-chemical 
properties of solvent cast buccal films incorporating OME for paediatric drug delivery were 
investigated.  
The DSC peak at 56.57°C and 63.31°C, can be attributed to evaporation of water and 
therefore possible that the scCO2 treated films absorbed some moisture during sample 
preparation for DSC analysis due to the highly dried nature. The endothermic peak at 133.49°C, 
suggests possibly recrystallized OME. However, the actual melting point of OME is 158°C 
(Khan et al., 2015) and therefore this peak could represent either a polymorphic form or a 
eutectic peak arising from combining L-arg and OME. The treatment with scCO2 seems to have 
enhanced the ease with which water molecules are removed (hence lower dehydration 
temperature) and also seems to have resulted in OME with lower melting points. The higher 
residual water in scCO2 treated films is interesting as it suggests that the equilibrium residual 
moisture content of scCO2 treated films is dependent on the drug (OME) content and possibly 
also affected by L-arg since this was required to stabilize OME in the DL films. The scCO2 
process appears to have generated a film matrix that allows rapid evaporation of residual 
moisture, through the preservation of the swollen structures (Gin et al., 2009). To confirm the 
observed crystals as recrystallized drug, SEM and XRD was used.  
The differences in surface topography could be attributed to CO2 entering the film matrix and 
drying the film by removing trapped solvent and causing some of the drug to molecularly 
dispersed drug to recrystallize on the film surface (Lan et al., 2011). The 5% crystallinity of 
DL MET film treated in scCO2 in Figure 4b (2-theta peak 9° and 24°) correspond to the XRD 
peaks of OME as shown in Figures 5a and 5b (Khan et al., 2015) for the pure drug and physical 
mixtures respectively. This confirms the DSC and SEM results which suggests possible 
recrystallization of a small amount of the molecularly dispersed OME present in the original 
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DL films. Further, the XRD diffractogram for the physical mixture of the four starting materials 
(OME, L-arg, PEG400 and MET) contains peaks found in all the pure starting materials, 
implying very little interaction in the physical mixtures, unlike the case of DL films, where 
most of the components were largely amorphous, with the exception of the small amounts of 
OME which appeared crystalline after scCO2 treatment. 
The various unique IR peaks observed for the different films analysed indicated that 
the physical property of both BLK and DL loaded films did change via new physical and 
chemical interactions between the main components (i.e. polymer and PEG for BLK films and 
polymer, PEG, OME and L-arg for DL films) with scCO2 treatment. It further confirms the 
hypothesis that scCO2 treatment is able to significantly alter performance characteristics of thin 
films by altering the functional physico-chemical properties. 
The significant changes in hydration properties of the films with scCO2 treatment is 
expected to impact on the drug release characteristics of the treated films once in contact with 
saliva. The main step of scCO2 consists of the anomalous swelling of polymer thin films 
caused by scCO2 within the film matrix. This could be due to the fact that scCO2 dried these 
films in a far more efficient manner and the resulting films were most probably more porous 
than the original ones. They fell apart as soon as they came in contact with water as they were 
‘charged’ to have a high affinity for water due to a higher specific surface area (Li et al., 
2007; Pham et al., 2003).  
The reduced mucoadhesion of the treated films is can be explained by the swelling 
results discussed above. In the case of the non-treated films, the formulations hydrated more 
slowly and formed a swollen gel without disintegrating, which allowed formation of stronger 
physical interactions between the swollen polymer (MET) and the model mucosa (gelatine gel) 
surface. In the case of the scCO2 treated films, the rapid hydration and eventual disintegration 
of the hydrated matrix will have quickly formed a low viscosity gel which flows easily and 
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therefore had weaker interaction and shorter contact time with the surface of the gelatine gel. 
This is interesting and can be explained by the diffusion theory of mucoadhesion where the 
initial swelling stage is necessary to allow for inter-molecular diffusion between the polymeric 
chains and that of the mucosa surface to consolidate adhesive forces. However, if this initial 
hydration and swelling is too rapid, it results in the formation of a slippery mucilage which is 
less adhesive (Ayensu et al., 2012; Pawar et al., 2014).  
The higher cumulative release in scCO2 treated DL film is related to rapid disintegration 
as observed in the hydration (swelling) data. The slower release of OME from the non-treated 
film could be attributed to the initial swelling of the polymeric network of MET over a longer 
period to form a more viscous gel which controls the diffusion of drug into the dissolution 
medium. It is also interesting to note that unlike the non-treated films, which showed a 
sustained release profile, the scCO2 treated films showed two phases of release. The first phase 
up to 10 minutes released a total of 94% before it plateaued in the second phase. The different 
phases suggests different mechanisms may be at play during dissolution most likely a 
combination of drug diffusion and erosion/disintegration which eventually ‘dumps’ most of 
the drug into the medium. The comparison of release profiles goes to confirm the conversion 




In previous studies (Khan et al., 2015, 2016), we developed mucoadhesive and 
sustained release MET based films incorporating OME as a model drug and L-arg as 
stabilising agent to prevent drug degradation. Functional characterisation showed release of 
the drug and subsequent permeation through pig buccal tissues over a two hour period, owing 
to prolonged retention at the buccal mucosa surface. Different studies report a residence time 
and ideal release period ranging from 2 – 6 hours (Choi et al., 2000; Figueiras et al., 2009; 
Khan et al., 2015; Trastullo et al., 2016) with the maximum usually between 4 – 6 hours. We 
opted for the lower time period of 2 hours (Khan et al., 2015, 2016), taking into consideration 
the expected difficulty of retaining formulations in the buccal region of paediatric patients for 
prolonged periods, for example challenges such as feeding and tongue movements. This 
study has shown that treatment of the sustained release films with scCO2 changed them into 
rapid release formulations as observed in the results above.  
 Overall, the lower adhesion on the model buccal mucosa and higher in vitro release 
profile of the scCO2 treated formulations could contribute to concentration of the free drug in 
saliva within a short period of time. For buccal films intended for only buccal mucosa 
delivery, the ideal situation is for the drug to be concentrated in the buccal mucosa in a time 
compatible with its absorption, which was relatively short in the case of the treated films.  
This could result in a situation where all the rapidly released drug is not completely absorbed 
across the buccal mucosa. As a consequence, some of the drug present in the saliva will be 
absorbed in other regions such as sublingual and GIT after swallowing. However, a study by 
Choi and Kim (2000) investigating the absorption of OME across human oral cavity, they 
showed that about 23% of the administered dose was absorbed from the oral cavity in 15 min 
after the administration of OME solutions. Therefore, though a significant amount of OME 
was released from the scCO2 treated films, within 30 minutes, it is still possible that enough 
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could be absorbed across the buccal mucosa and sublingual route to elicit the desired 
systemic therapeutic action.  
In a recent study, Chonkar and co-workers developed fast dissolving HPMC based 
buccal films incorporating nanoparticles loaded with lercanidipine and showed high 
dissolution rates and improved ex-vivo permeation through porcine buccal mucosa (Chonkar 
et al., 2016). Haque and Sheela (2015), developed polymer-bound fast dissolving buccal 
films of chitosan containing different disintegrating agents, for buccal delivery of metformin 
hydrochloride. They showed that disintegration time was less than 30 minutes for all 
formulations, attributed to the effect of the disintegrants. The optimum formulation 
combining sodium starch glycolate and microcrystalline cellulose, released 92.2% within 6 
minutes which was deemed appropriate for rapid absorption across the buccal mucosa. A 
buccal mucoadhesive fast dissolving film was developed using pullulan as the main 
component and physically evaluated for moisture content, disintegration time, and 
mucoadhesion. The films showed respective values 14%, 41.6 seconds and 40 kg/cm2 for 
moisture content, disintegration time and mucoadhesive force, which were deemed 
appropriate (Vila et al., 2014). These values were not too different from that obtained in the 
current study.  
Further, given that it can be challenging for a younger paediatric patient to hold a film 
in the buccal region long enough, whilst some find it difficult to swallow significant amounts 
of liquid formulations due to possible vomiting, use of rapid disintegrating films of OME 
combining both oral mucosa (buccal, sublingual) and GIT absorption appear to be will be a 
feasible approach to paediatric delivery of OME. In addition, the volume of hydration and 
dissolution medium used to hydrate the films at a given time point, is significantly higher 
than that produced by a normal paediatric patient, and therefore it will be expected to hydrate 




The results show that scCO2 caused significant changes to the physical properties and 
functional performance characteristics of the MET films and converted the original DL MET 
films from a sustained release formulation to a fast dissolving drug release system, releasing > 
90% of OME within 15 minutes. Therefore, scCO2 drying can offer real opportunities for the 
formulation of fast dissolving thin films with the potential for paediatric buccal administration 
and subsequently easily swallowed with little difficulty. Though the release within 15 minutes 
is short, this could prove ideal for children with swallowing difficulties, by the combination of 
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Figure 1 Digital images showing physical appearance of (a) non-treated BLK films, (b) non- 
treated DL films, (c) scCO2 treated BLK films (d) scCO2 treated DL films. 
 
Figure 2 DSC thermograms of (a) scCO2 treated and non-treated BLK MET films and (b) 
scCO2 treated and non-treated DL MET films. 
 
Figure 3 SEM micrographs of (a) pure OME (b) pure L-arg, (c) scCO2 treated BLK films and 
(d) sCO2 treated DL films. 
 





Figure 5 (a) XRD diffractograms for the pure MET, OME, L-arg and PEG 400 and (b) XRD 
diffractogram of physical mixture comprising film formulation components (MET, OME, L-
arg and PEG 400) 
 
Figure 6 FT-IR spectra of (a) BLK films with and without scCO2 treatment and (b) DL films 
with and without scCO2 treatment. 
 
Figure 7 In-vitro mucoadhesion profiles of (a) BLK film and (b) DL film with and without 
scCO2 treatment (mean ± SD, n = 3). 
 
Figure 8 Drug dissolution profiles showing cumulative percent release against time of OME 
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